Envista vs Solventum
NVST and SOLV side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NVST and SOLV compare
Solventum is the larger company, worth 3.8 times as much as Envista ($15.1B against $4.0B).
On earnings, Envista is cheaper: it trades at 6.4× trailing earnings, against 99.8× for Solventum.
Envista grew revenue faster over the last twelve months (9.8% versus −2.8% for Solventum).
Envista keeps more of each dollar of sales as profit, with a net margin of 22.0% compared with 1.9% at Solventum.
Envista scores higher on the StockData Score (17 against 6 for Solventum), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NVST | SOLV |
|---|---|---|
| Size and price | ||
| Market cap | $4.0B | $15.1B |
| Share price | $24.66 | $88.81 |
| Change, 1 year | 22.0% | 20.2% |
| Change, 5 years | −41.4% | – |
| Beta (5Y) | 0.94 | 0.51 |
| Employees | 12K | 10K |
| StockData Score | ||
| Total score | 17 (better) | 6 |
| Valuation score | 6 (better) | 1 |
| Growth score | 3 (better) | 2 |
| Performance score | 5 (better) | 2 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 6.4× (better) | 99.8× |
| P/S | 1.4× (better) | 1.9× |
| P/B | 1.3× (better) | 3.1× |
| EV/EBITDA | 5.0× (better) | 20.2× |
| P/FCF | 16.4× | – |
| PEG | – | 22.14 |
| FCF yield | 6.1% (better) | 0.00% |
| Fair value | $94.66 | $45.74 |
| Margin of safety | 73.9% (better) | −94.2% |
| Growth | ||
| Revenue growth (TTM) | 9.8% (better) | −2.8% |
| Revenue growth, 5Y average | 7.1% | – |
| Net income growth (TTM) | 4041% (better) | −89.8% |
| EPS growth (TTM) | 4200% (better) | −89.8% |
| EPS growth, 5Y average | 7.0% | – |
| Profitability | ||
| Gross margin | 55.9% (better) | 54.8% |
| Operating margin | 25.4% (better) | 5.6% |
| Net margin | 22.0% (better) | 1.9% |
| FCF margin | 8.4% (better) | 0.00% |
| Return on equity | 20.5% (better) | 3.2% |
| Return on invested capital | 20.0% (better) | 4.7% |
| Financial health | ||
| Debt / equity | 0.46 (better) | 1.05 |
| Net debt / EBITDA | 0.32 (better) | 4.74 |
| Current ratio | 2.45 (better) | 1.03 |
| Altman Z-score | 2.18 (better) | 1.85 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | 3.5% | – |
| Shareholder yield | 3.5% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 118% | 75.0% |
| Held by insiders | 0.85% | 30.3% |
| Insider net buying, 12 months | −$510K | $100K (better) |
| Superinvestors holding | 2 | 2 |
| Short interest, % of float | 6.1% | 4.3% |
Go deeper
- NVST stock overview
- NVST income statement
- NVST valuation and score
- SOLV stock overview
- SOLV income statement
- SOLV valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.